Table 2 Clinical characteristics of TP53mut MDS and AML cohort.
Variables | Overall (n = 603) |
|---|---|
Female/male | 221 (36.7%)/382 (63.3%) |
Age at MN diagnosis, median [IQR] | 68.60 [62.00, 75.00] |
Blood counts and marrow blast, median [IQR] | |
Hemoglobin, g/L | 9.00 [7.90, 10.50] |
WBC | 3.00 [1.80, 5.10] |
Platelets | 55.00 [30.00, 106.00] |
PB blasts % | 1.00 [0.00, 7.00] |
BM blasts % | 8.90 [2.50, 27.25] |
Disease phenotype (%) | |
AML | 229 (38%) |
MDS | 374 (62%) |
Cytogenetic changes, n (%)a | |
Complex karyotype | 484 (80.7%) |
Monosomal karyotype | 437 (72.8%) |
Deletion 5q | 441 (73.9%) |
Deletion 7q | 306 (51.3%) |
Deletion 17p | 240 (40.2%) |
TP53 mutation characteristics | |
TP53mut VAF (median, IQR) | 36.80% (19.6, 59.0) |
TP53mut VAF ≥ 2% | 603 (100%) |
TP53mut VAF ≥ 10% | 520 (86.2%) |
TP53mut VAF < 10% | 83 (13.8%) |
Somatic co-mutations on NGS, n (%) | |
TET2 | 66 (10.9%) |
DNMT3A | 63 (10.4%) |
ASXL1 | 48 (8.0%) |
SF3B1 | 33 (5.5%) |
RUNX1 | 29 (4.8%) |
SRSF2 | 29 (4.8%) |
JAK2 | 27 (4.5%) |
U2AF1 | 25 (4.1%) |
RAS | 20 (3.3%) |
EZH2 | 16 (2.7%) |
BCOR | 15 (2.5%) |
IDH2 | 12 (2.0%) |
PTPN11 | 11 (1.8%) |
CBL | 7 (1.2%) |
CEBPAb | 7 (1.2%) |
ZRSR2 | 6 (1.0%) |
First line therapy n (%)c | |
Hypomethylating agents | 214 (36.4%) |
Venetoclax-based therapies | 111 (18.9%) |
Allogeneic stem cell transplantation | 99 (16.4%) |
Intensive chemotherapy | 96 (16.3%) |
Lenalidomide | 20 (3.4%) |
Erythropoietin/Erythroid differentiation agents | 19 (3.2%) |
Other therapies | 9 (1.5%) |
Supportive therapy | 111 (18.9%) |
